Heritas Capital co-leads Hummingbird Bioscience’s extended Series A

Antibody visual sourced from Hummingbird's website

Biotech company Hummingbird Bioscience has announced the completion of an extended Series A funding round led by Singapore-based Heritas Capital Management and SEEDS Capital, the investment arm of Enterprise Singapore.

Existing backer and Series A lead investor Decheng Capital also participated in the latest financing.

Hummingbird focuses on the discovery and development of novel antibody-based therapeutics. The biotech firm will use the fresh capital infusion to advance is anti-VISTA and anti-HER3 programs to first-in-human clinical trials. The company will also expand its laboratory facilities.

“Hummingbird’s computational biology-driven drug discovery platform, which has since yielded two high-potential pre-clinical stage drug compounds, represents early inroads of Singapore’s investments into biopharmaceutical R&D,” said SEEDS Capital general manager Geoffrey Yeo.

As part of the financing, Heritas Capital Management CEO and executive director Chik Wai Chiew and Decheng Capital partner Victor Tong will join the Hummingbird board. Heritas, a private equity and venture capital investor based in Singapore, made the investment through the Heritas Venture Fund.

The company had received a $13.1-million product development grant in February from the Cancer Prevention and Research Institute of Texas. The grant will support clinical trials of its anti-VISTA antibody for the treatment of solid tumours and lymphomas unresponsive to existing therapies.

Hummingbird has operating locations in Houston, Texas; South San Fransisco, California; as well as Singapore.